<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433095</url>
  </required_header>
  <id_info>
    <org_study_id>Mamma-2-2004</org_study_id>
    <nct_id>NCT00433095</nct_id>
  </id_info>
  <brief_title>Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <brief_summary>
    <textblock>
      1st-line treatment of HER2/neu overexpressing breast cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The combination of vinorelbine and trastuzumab was demonstrated to be highly effective in&#xD;
      several trials showing response rates in the range of 59-78%. This combination is&#xD;
      characterized by good tolerability and can be applied for a prolonged period without the risk&#xD;
      of major cumulative toxicity The availability of oral vinorelbine promises a further&#xD;
      simplification of therapy. The present trial therefore investigates the safety and efficacy&#xD;
      of a combined treatment with trastuzumab and oral vinorelbine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <condition>Carcinoma Breast Stage IV</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Navelbine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Navelbine (oraly)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven, metastatic breats cancer.&#xD;
&#xD;
          -  HER2-neu overexpression (IHC3+ or IHC2+/FISH+)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  no previous therapy with vinorelbine or trastuzumab&#xD;
&#xD;
          -  Age * 18 and * 75 years&#xD;
&#xD;
          -  Karnofsky-Performance status &gt; 70%&#xD;
&#xD;
          -  Life expectance 16 weeks and more&#xD;
&#xD;
          -  Availability of at least one target lesion according to RECIST-criteria. Target&#xD;
             lesions need to be outside of radiation fields. Bone metastases are excluded as&#xD;
             indicator leasions&#xD;
&#xD;
          -  Exclusion of pregnancy and adequte contraception during childbearing age.&#xD;
&#xD;
               -  Adequate hematological, renal, and hepatic function&#xD;
&#xD;
          -  Normal cardiac function. LVEF should not be &gt;10% below normal.&#xD;
&#xD;
          -  Adequate compliance to perform treatment and subsequent follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Locoregional recurrence of breast cancer only or development of contralateral breast&#xD;
             cancer&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Symptomatic brain- or meningeal metastasis&#xD;
&#xD;
          -  Concurrent endocrine antitumor therapy&#xD;
&#xD;
          -  Other malignancies except basal cell cancer of the skin or in-situ carcinoma of the&#xD;
             cervix&#xD;
&#xD;
          -  Peripheral neuropathy &gt;= NCI CTC Grade 2.&#xD;
&#xD;
          -  other severel disease which preclude adequate treatment&#xD;
&#xD;
          -  Participation in a clinical trial within the last 30 days.&#xD;
&#xD;
          -  Psychological, familial, sociological or geographical conditions which preclude&#xD;
             treatment according to the protocol or the planned follow-up&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Volker Heinemann, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Munich - Klinikum Grosshadern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans-Joachim Stemmler, PhD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Munich - Klinikum Grosshadern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Munich - Klinikum Grosshdern</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <study_first_submitted>February 7, 2007</study_first_submitted>
  <study_first_submitted_qc>February 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2007</study_first_posted>
  <last_update_submitted>March 11, 2011</last_update_submitted>
  <last_update_submitted_qc>March 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2011</last_update_posted>
  <keyword>Navelbine</keyword>
  <keyword>Herceptin</keyword>
  <keyword>oral</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

